High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience.

Bosly, André;Haioun, C.;Gisselbrecht, C.;Reyes, F.;Coiffier, B.
(2001) European Journal of Haematology. Supplementum —

Files

27486.pdf
  • Restricted Access
  • Adobe PDF
  • 4.73 MB
Request a copy

Details

Authors
  • Bosly, AndréUCLouvain
    Author
  • Haioun, C.
    Author
  • Gisselbrecht, C.
    Author
  • Reyes, F.
    Author
  • Coiffier, B.
    Author
Abstract
Autologous stem-cell transplantation (ASCT) has permitted to deliver high-dose therapy (HDT). In aggressive lymphomas, the GELA group conducted prospective and retrospective studies comparing HDT + ASCT to conventional sequential chemotherapy. In relapsing patients and in partial remission, retrospective studies showed a survival advantage for HDT + ASCT over sequential chemotherapy. In complete response, advantage for HDT + ASCT was demonstrated in a prospective trial only for patients with high intermediate or high risk in the IPI score. The attainment of a maximal reduction of the tumoral mass before going HDT is very important either in first line or in relapsing patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bosly, A., Haioun, C., Gisselbrecht, C., Reyes, F., & Coiffier, B. (2001). High-dose treatment with autologous stem cell transplantation versus sequential chemotherapy: the GELA experience. European Journal of Haematology. Supplementum. https://hdl.handle.net/2078.5/99326